• Cl-Amidine trifluoroacetate salt: PAD4 Inhibition in Cancer

  2026-06-13

  Cl-Amidine (trifluoroacetate salt) empowers researchers to dissect PAD4-driven gene regulation in models of cancer, autoimmunity, and inflammation with unprecedented specificity. This guide decodes the latest applied protocols, troubleshooting tactics, and experimental insights, connecting frontline leukemia research to practical PAD4 inhibition workflows.

• RP3-340N1.2 Knockdown Impairs NSCLC via IL-6 mRNA Destabiliz

  2026-06-12

  This study uncovers a novel mechanism by which the lncRNA RP3-340N1.2 promotes non-small cell lung cancer (NSCLC) progression through stabilization of IL-6 mRNA. Targeted knockdown of RP3-340N1.2 enhances IL-6 mRNA degradation, suppressing tumor cell proliferation, migration, and pro-tumor macrophage polarization—highlighting a potential RNA-based therapeutic target in NSCLC.

• M344: Advancing HDAC Inhibition in Cancer and HIV Research

  2026-06-12

  M344, a potent histone deacetylase inhibitor, is reshaping translational research in oncology and virology. This article offers mechanistic insights and strategic guidance for leveraging M344 in cell differentiation, apoptosis, and viral latency models. By synthesizing current evidence, expert protocols, and competitive benchmarking, we highlight how M344 enables new approaches to therapy resistance and latent infection challenges.

• Radicicol Beyond Hsp90: Multi-Pathway Modulation in Disease

  2026-06-11

  Explore how Radicicol, a potent Hsp90 inhibitor, uniquely enables multi-pathway analysis in disease models—including apoptosis, adipogenesis, and inflammatory assays. This deep dive reveals Radicicol’s mechanistic versatility, advanced assay considerations, and its role in the evolving landscape of metabolic and cancer research.

• EV-Transferred ACLY Drives TAM Differentiation in HCC Progre

  2026-06-11

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles carrying ATP-citrate lyase (ACLY), which are taken up by monocytes to induce their differentiation into immunosuppressive tumor-associated macrophages (TAMs). These findings illuminate a metabolic mechanism by which HCC modulates the tumor microenvironment and suggest new avenues for immunotherapy targeting EV-mediated enzyme transfer.

• Itraconazole for Advanced Antifungal Biofilm Research

  2026-06-10

  Itraconazole, a triazole antifungal agent, is redefining research workflows in the fight against biofilm-mediated resistance in Candida species. This guide translates the latest mechanistic insights and protocol advances into actionable strategies for optimizing antifungal drug interaction studies and disseminated candidiasis models.

• OTUD3 Stabilizes SLC7A11 to Drive Sunitinib Resistance in cc

  2026-06-10

  This study uncovers how OTUD3 overexpression in clear cell renal cell carcinoma (ccRCC) stabilizes the cystine transporter SLC7A11, suppressing ferroptosis and promoting resistance to sunitinib. These mechanistic insights highlight new therapeutic targets and reinforce the importance of precise lipid peroxidation measurement in translational oncology research.

• Ferrostatin-1 (Fer-1): Optimizing Ferroptosis Assays in Canc

  2026-06-09

  Ferrostatin-1 (Fer-1) enables precise and reproducible inhibition of ferroptosis, streamlining mechanistic studies in cancer and neurodegenerative models. This article integrates novel findings and advanced workflows to help researchers maximize assay sensitivity and troubleshoot common pitfalls in oxidative lipid damage inhibition.

• MK 0893: Potent Glucagon Receptor Antagonist for Type 2 Diab

  2026-06-09

  MK 0893 is a selective, reversible glucagon receptor antagonist with nanomolar potency and high selectivity, used widely in type 2 diabetes research. It inhibits cAMP production and blood glucose excursions in preclinical models and clinical studies, supporting both mechanistic and translational research.

• Unlocking Propranolol’s Mechanistic Power for Translational

  2026-06-08

  This thought-leadership article explores the mechanistic depth and translational potential of Propranolol—a non-selective β-adrenergic receptor blocker—highlighting new metabolomic insights, strategic guidance for cardiovascular and metabolic researchers, and practical protocol recommendations. By leveraging the latest clinical trial data and cross-referencing established workflows, we offer a forward-looking roadmap for deploying Propranolol in innovative preclinical and clinical research.

• Hemagglutinin mRNA Vaccine Protects Dairy Cows from H5N1 Cha

  2026-06-08

  This study demonstrates that a hemagglutinin-based mRNA–lipid nanoparticle vaccine confers robust and durable protection against highly pathogenic H5N1 influenza in lactating dairy cows. The findings establish the feasibility of mRNA vaccine strategies for livestock, offering significant implications for controlling zoonotic influenza outbreaks and safeguarding both animal and public health.

• FOXM1–ERα ceRNA Networks as Biomarkers in Female Lung Adenoc

  2026-06-07

  This study identifies and validates a novel ceRNA network involving FOXM1 and estrogen receptor alpha (ERα) in female lung adenocarcinoma, revealing its prognostic significance and potential to guide immunotherapy responsiveness. The integrative approach combining bioinformatics, clinical analysis, and experimental validation provides mechanistic insights into LUAD progression and highlights new biomarker candidates.

• Broad-Spectrum Bivalent mRNA Vaccine Neutralizes SARS-CoV-2

  2026-06-06

  A recent preclinical study introduces RQ3025, a bivalent mRNA vaccine designed to target multiple SARS-CoV-2 variants by encoding spike protein mutations observed across major lineages. The research demonstrates that RQ3025 elicits broad neutralizing antibody responses and a Th1-biased cellular immunity in animal models, supporting its potential for next-generation COVID-19 vaccination strategies.

• Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer to P

  2026-06-05

  Mei et al. demonstrate that hyperthermia-induced BRCA2 protein reduction creates synthetic vulnerability to PARP inhibitor therapy in BRCA2-proficient ovarian carcinoma. This combinatorial approach overcomes a major resistance mechanism and provides a new research direction for enhancing DNA damage repair inhibition strategies in ovarian cancer.

• Nicotinamide Adenine Dinucleotide (NAD+): Redefining Stress

  2026-06-05

  Explore how Nicotinamide Adenine Dinucleotide (NAD+) orchestrates cellular stress adaptation and DNA damage responses in human models, offering unique mechanistic insights and practical guidance for advanced biochemical research. This article unveils new assay strategies and contextualizes NAD+ within the latest caspase-driven autophagy findings.

15287 records 1/1020 page Next 12345 下5页 Last page